LMR Partners LLP Takes Position in Illumina, Inc. (NASDAQ:ILMN)

LMR Partners LLP purchased a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 21,285 shares of the life sciences company's stock, valued at approximately $2,776,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Freemont Management S.A. acquired a new stake in Illumina in the third quarter valued at $1,565,000. Cetera Advisors LLC acquired a new position in Illumina in the first quarter valued at approximately $610,000. Weybosset Research & Management LLC increased its stake in Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company's stock valued at $2,354,000 after purchasing an additional 8,650 shares during the last quarter. B. Riley Wealth Advisors Inc. raised its holdings in Illumina by 176.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company's stock worth $749,000 after purchasing an additional 4,579 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Illumina by 3.6% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 399,966 shares of the life sciences company's stock valued at $41,748,000 after buying an additional 13,725 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Price Performance

Shares of ILMN traded up $4.26 during trading hours on Tuesday, reaching $135.00. 3,125,264 shares of the company traded hands, compared to its average volume of 2,027,207. The stock has a market capitalization of $21.41 billion, a PE ratio of -13.13 and a beta of 1.13. The stock has a fifty day simple moving average of $139.82 and a 200 day simple moving average of $124.35. Illumina, Inc. has a fifty-two week low of $93.39 and a fifty-two week high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analysts' expectations of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The firm's revenue for the quarter was down 3.5% compared to the same quarter last year. During the same period last year, the company earned $0.33 EPS. As a group, research analysts predict that Illumina, Inc. will post 4.11 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Royal Bank of Canada upped their price objective on shares of Illumina from $252.00 to $254.00 and gave the company an "outperform" rating in a research note on Tuesday, November 5th. Robert W. Baird boosted their price objective on Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research note on Wednesday, November 6th. TD Cowen raised their target price on shares of Illumina from $166.00 to $177.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. StockNews.com initiated coverage on shares of Illumina in a research report on Thursday, August 29th. They set a "buy" rating on the stock. Finally, UBS Group boosted their price target on Illumina from $133.00 to $145.00 and gave the company a "neutral" rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $164.00.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.